eXoZymes Inc. announced a significant biomanufacturing breakthrough on September 23, 2025, detailing the successful gram-scale production of N-trans-caffeoyltyramine (NCT). This achievement was accomplished using the company's AI-driven exozymes platform.
The NCT project progressed from concept to lab-scale validation with gram-scale production in only five months. This rapid development was achieved at a fraction of the normal synthetic biology research and development cost, demonstrating the platform's efficiency.
Specifically, the NCTx subsidiary demonstrated lab scale validation with 4 grams of NCT produced at a 96% yield and with a purity higher than 99%. This high yield and purity underscore the precision and effectiveness of eXoZymes' proprietary biomanufacturing approach for valuable bioactive compounds.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.